Hypothyroidism News and Research

RSS

Hypothyroidism occurs when the thyroid gland does not produce enough thyroid hormone to meet the body’s needs. Without enough thyroid hormone, many of the body’s functions slow down. About 5 percent of the U.S. population has hypothyroidism. Women are much more likely than men to develop hypothyroidism.

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).

1 Aug 2011

New ATA guidelines on diagnosis and management of thyroid disease during pregnancy

Emerging data clarifying the risks of insufficient thyroid activity during pregnancy on the health of the mother and fetus, and on the future intellectual development of the child, have led to new clinical guidelines for diagnosing and managing thyroid disease during this critical period.

26 Jul 2011

Newborn study suggests that increase in congenital hypothyroidism is entirely artifactual

A new study that was prompted by recent reports of an increase in cases of congenital hypothyroidism in the United States, and aimed at assessing the incidence of this condition among Quebec newborns, suggests that the increase is entirely artifactual.

19 Jul 2011

Avoidance of routine thyroid testing on pregnant women would have let 80% of cases go undetected

A recent study completed by researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) demonstrates that BMC conducts a high rate of thyroid function testing in pregnant women.

1 Jul 2011

Acura, Pfizer receive FDA approval for OXECTA Tablets to manage severe pain

Pfizer Inc. and Acura Pharmaceuticals Inc. announce the marketing approval from the U.S. Food and Drug Administration (FDA) of OXECTATM Tablets CII.

20 Jun 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Older adults with subclinical hyperthyroidism may face higher risk of dying

A common hormone abnormality in older adults—a mild form of overactive thyroid called subclinical hyperthyroidism—is linked to a much higher risk of dying, a new study finds. The results will be presented Sunday at The Endocrine Society's 93rd Annual Meeting in Boston.

6 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

ATA recognizes 4th Annual World Thyroid Day

The American Thyroid Association, in cooperation with sister international thyroid societies, the European Thyroid Association, the Asia & Oceania Thyroid Association, and the Latin American Thyroid Society, recognizes the 4th Annual World Thyroid Day, May 25, 2011.

26 May 2011

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

TPO antibodies linked to abnormal thyroid levels in women after giving birth

Almost 1 in 20 women who gives birth will go on to develop thyroid problems within two years, according to a new study presented at the European Congress of Endocrinology in Rotterdam. This could have significant implications for the future health of the mother and child, as well as potentially presenting problems for future pregnancies.

4 May 2011

Weight-loss physician unveils unique reduced-calorie eating plan

"Forget everything you think you know about losing weight," says a prominent weight-loss doctor. "The conventional wisdom on weight loss has helped make the majority of Americans overweight or obese."

2 May 2011

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

25 Apr 2011

Obesity impacts gene clock of cardiovascular system

Obese individuals typically suffer more medical problems than their leaner counterparts. They are more likely to be diagnosed with insulin resistance, diabetes, increased stress hormones, hypothyroidism, and sleep apnea. Researchers at the Georgia Health Sciences University in Augusta have also found the potential for something else, using an animal model.

12 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Experts issue joint statement to help Americans understand radiation-related health risks

The growing concern surrounding the release of radiation from an earthquake and tsunami-stricken nuclear complex in Japan has raised fears of radiation exposure to populations in North America from the potential plume of radioactivity crossing the Pacific Ocean.

19 Mar 2011

Hypothyroidism News and Research

Further Reading

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

New ATA guidelines on diagnosis and management of thyroid disease during pregnancy

Newborn study suggests that increase in congenital hypothyroidism is entirely artifactual

Avoidance of routine thyroid testing on pregnant women would have let 80% of cases go undetected

Acura, Pfizer receive FDA approval for OXECTA Tablets to manage severe pain

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Older adults with subclinical hyperthyroidism may face higher risk of dying

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

ATA recognizes 4th Annual World Thyroid Day

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

TPO antibodies linked to abnormal thyroid levels in women after giving birth

Weight-loss physician unveils unique reduced-calorie eating plan

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

Obesity impacts gene clock of cardiovascular system

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Experts issue joint statement to help Americans understand radiation-related health risks

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News